Abstract

Provided herein are antibodies and antigen binding fragments that are capable of binding to a betacoronavirus, e.g. a sarbecovirus selected from one or more of SARS-CoV-2, SARS-CoV-2 omicron, SARS-CoV-2 beta, SARS-CoV-1, WIV-1, RaTG13, and SCH014.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61K 39/42 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral

Abstract

Embodiments herein provide systems and methods to identify gastric dysfunction. Many embodiments utilize ECG and/or EGG measurements for an individual to determine autonomic modulation and/or gastric motility modulation. Additional embodiments utilize functional principal components analysis to identify features present in ECG and/or EGG that can distinguish phenotypes (e.g., healthy, dysfunctional, etc.) based on scoring features extracted from ECG and/or EGG trace data. Further embodiments provide diagnostic and/or treatments to the individual based on an identified phenotype.

IPC Classes  ?

• A61B 5/392 - Detecting gastrointestinal contractions
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/318 - Heart-related electrical modalities, e.g. electrocardiography [ECG]
• A61B 5/0538 - Measuring electrical impedance or conductance of a portion of the body invasively, e.g. using a catheter
• A61B 5/285 - Endotracheal, oesophageal or gastric probes

Abstract

The present disclosure provides methods and compositions for tunable differentiation of hematopoietic stem and progenitor cells (HSPCs) in response to small molecules by using genetically modified HSPCs that express chimeric transmembrane receptors.

IPC Classes  ?

• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• A61K 38/16 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

Aspects of the present disclosure include methods for making a polymeric structure having a micro-void space. Methods according to certain embodiments include irradiating a polymerizable composition positioned between a build elevator and a build surface to generate a polymerizable composition having a polymerized region of the polymerizable composition having a micro-void space in contact with the build elevator and a non-polymerized region of the polymerizable composition in contact with the build surface, displacing the build elevator away from the build surface, contacting the generated micro-void space with a non-reactive composition and repeating in a manner sufficient to generate a polymeric structure having a resolved micro-void space. Systems for preparing a polymeric structure according to the subject methods are also described. Polymeric structures having a resolved micro-void space such as where the micro-void space is filled with a non-polymerizable composition are also provided.

IPC Classes  ?

• B29C 64/124 - Processes of additive manufacturing using only liquids or viscous materials, e.g. depositing a continuous bead of viscous material using layers of liquid which are selectively solidified
• B29C 64/245 - Platforms or substrates
• B29C 64/232 - Driving means for motion along the axis orthogonal to the plane of a layer
• B29C 64/264 - Arrangements for irradiation
• B33Y 10/00 - Processes of additive manufacturing
• B33Y 30/00 - ADDITIVE MANUFACTURING, i.e. MANUFACTURING OF THREE-DIMENSIONAL [3D] OBJECTS BY ADDITIVE DEPOSITION, ADDITIVE AGGLOMERATION OR ADDITIVE LAYERING, e.g. BY 3D PRINTING, STEREOLITHOGRAPHY OR SELECTIVE LASER SINTERING - Details thereof or accessories therefor
• B33Y 80/00 - Products made by additive manufacturing
• B01F 33/30 - Micromixers
• A61M 37/00 - Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
• B29L 31/00 - Other particular articles

Abstract

Embodiments herein describe systems and methods to enhance RNA stability and uses thereof. Many embodiments alter the sequence of an RNA therapeutic molecule (e.g., vaccines) to encode for a variant peptide while maintaining and/or increasing stability of the RNA therapeutic.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Provided are methods for the isolation of phorbol from seed sources and the use of the phorbol for the generation of tigliane tiglate and derivatives thereof.

IPC Classes  ?

• C07D 303/14 - Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by free hydroxyl radicals
• A61K 31/122 - Ketones having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• A61K 36/47 - Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)

Abstract

Imaging devices, systems, and methods are provided for imaging using narrow bands of short wavelength infrared (SWIR) light, e.g., to image at water absorption wavelength and/or to image through blood. In one example, an imaging device is provided for imaging during a medical procedure that includes a proximal end, a distal end sized for introduction into a subject's body, and an imaging element carried by the distal end, a light source coupled to the imaging device to deliver one or both of narrow band short wavelength infrared (SWIR) light and visible light, and a camera for acquiring images via the imaging element.

IPC Classes  ?

• A61B 1/04 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor combined with photographic or television appliances
• A61B 1/06 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor with illuminating arrangements
• A61B 1/00 - Instruments for performing medical examinations of the interior of cavities or tubes of the body by visual or photographical inspection, e.g. endoscopes; Illuminating arrangements therefor

Abstract

In certain aspects, the present invention provides methods for inducing a stable gene modification of a target nucleic acid via homologous recombination in a primary cell, such as a primary blood cell and/or a primary mesenchymal cell. In certain other aspects, the present invention provides methods for enriching a population of genetically modified primary cells having targeted integration at a target nucleic acid. The methods of the present invention rely on the introduction of a DNA nuclease such as a Cas polypeptide and a homologous donor adeno-associated viral (AAV) vector into the primary cell to mediate targeted integration of the target nucleic acid. Also provided herein are methods for preventing or treating a disease in a subject in need thereof by administering to the subject any of the genetically modified primary cells or pharmaceutical compositions described herein to prevent the disease or ameliorate one or more symptoms of the disease.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• A61K 31/7115 - Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• C07K 14/805 - Haemoglobins; Myoglobins
• C12N 5/0775 - Mesenchymal stem cells; Adipose-tissue derived stem cells
• C12N 5/0781 - B cells; Progenitors thereof
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells
• C12N 5/0789 - Stem cells; Multipotent progenitor cells
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• C12N 15/864 - Parvoviral vectors

Abstract

Gastrostomy tubes and systems and methods for implanting them are provided. In one example, the gastrostomy tube includes an elongate tubular member including a first end sized for introduction into the patient's mouth, a second end including an expandable member or other bumper, and a feeding lumen extending between the first and second ends. A bolster is connectable around the first end after the first end has been directed from within the patient's stomach through intervening tissue and extends from the patient's skin and the bumper is placed against the wall of the stomach. An adapter is connectable to the bolster after the first end and excess material of the tubular member beyond the bolster has been separated, the adapter including a connector for removably connecting to a feeding tube.

IPC Classes  ?

• A61J 15/00 - Feeding-tubes for therapeutic purposes

Abstract

Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61K 35/741 - Probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12N 1/20 - Bacteria; Culture media therefor
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

Compositions and methods are provided for the identification of peptide sequences that are ligands for a T cell receptor (TCR) of interest, in a given MHC context.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C07K 14/00 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof

Abstract

In exemplary methods, diamond is grown al low-temperature (e g., under 600° C or under 400° C) is grown. In one aspect, the method includes controlling growth of the diamond, during the diamond growth, by a gas chemistry that abates sp2 carbon formation and enhances diamond grain sizes in both lateral and vertical directions in the diamond while mitigating new diamond grains from forming on top of each other. As another aspect, the low-temperature diamond is grown on a wafer including one or more Si-based semiconductor devices adjacent and sufficiently close to a hot spot in a channel region of the semiconductor device(s) to cause, during operation of the semiconductor device(s), heat to be drawn from multiple sides of the hot spot, without undermining performance during operation of the semiconductor device(s).

Abstract

A wearable robotic device, called linear exoskeleton, is provided. The linear exoskeleton applies active assistance to reduce the knee contact forces during walking. The objective of the exoskeleton is to reduce knee contact force by using a motor to apply forces between a strap on the thigh and the ground. The force applied is controllable. The exoskeleton itself has a linear actuator type design, with a carriage that slides along a carbon pole.

IPC Classes  ?

• A61F 2/70 - Operating or control means electrical
• A61H 3/00 - Appliances for aiding patients or disabled persons to walk about
• A63B 23/035 - Exercising apparatus specially adapted for particular parts of the body for limbs, i.e. upper or lower limbs, e.g. simultaneously
• B25J 9/00 - Programme-controlled manipulators

Abstract

N-Acylated histidine dipeptides of formula N-Acylated histidine dipeptides of formula N-Acylated histidine dipeptides of formula are disclosed. The compounds are useful for treating breast cancer.

IPC Classes  ?

• C07K 5/078 - Dipeptides the first amino acid being heterocyclic, e.g. Pro, His, Trp
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein is a method that involves lysing cells that have a fusion between a first gene and a second gene at an end of an electrophoresis gel, applying a voltage potential to the gel to intact genomic DNA at one end of the gel, digesting the trapped genomic DNA using two or more pairs of RNA-guided endonucleases to release segments, electrophoresing the segments, eluting the segments into different fractions and analyzing the sequences nucleic acid collected in the fractions to identify a fraction that contains the segments of the first and second genes and a fraction that contains the segment of the gene fusion.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• G01N 27/447 - Systems using electrophoresis
• C12N 15/62 - DNA sequences coding for fusion proteins
• C12N 15/09 - Recombinant DNA-technology

Abstract

The present invention provides modified oligo(dT) primers containing at least one deliberate mismatch within the dT span of the primer which provides improved stability and replicability of the resulting cDNA molecules. In the context of RNA sequencing applications, incorporation of the modified oligo(dT) primers results in fewer sequence reads lost to PCR artifacts and easier detection of the end position of each sequence read.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
• C12Q 1/6841 - In situ hybridisation

Abstract

The present invention provides a set of robust, genetic-based assays to screen for common abnormalities that occur in cultured cells utilizing a digital PCR (dPCR) platform.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

222, and methane. The gas recovered from an off-gas collection system is beneficially used, such as for energy recovery while minimizing greenhouse gas emissions.

IPC Classes  ?

• C02F 3/12 - Activated sludge processes
• B01D 53/62 - Carbon oxides

Abstract

A high-resolution crystallographic structure of the mutant human G267S calpain-5 protease core domain at 2.22 Å resolution is provided. The G267S mutation is associated with hyperactivity of calpain-5 and is linked to the inherited disease, neovascular inflammatory vitreoretinopathy. Methods of using the crystallographic structure in rational design of small molecule drugs that inhibit calpain-5 for treatment of retinal diseases and other diseases associated with calpain-5 hyperactivity are also provided.

IPC Classes  ?

• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• G16C 20/50 - Molecular design, e.g. of drugs
• G16C 20/64 - Screening of libraries

Abstract

Aspects involve a stretchable composite film including a polymer material having at least a portion of the polymer material being densified through covalently-attached fluorination molecules. In certain specific examples, fluorinated molecules are covalently attached to a surface region, in the form of a layer or film (e.g., polymer semiconductor (PSC) film of a transistor substrate) to facilitate operational stability and/or to encapsulation performance (e.g., stretchability-related performance). In certain other specific examples, the surface region and a fluorinated layer are used in a cooperative configuration to provide stability in the PSC film in one or more harsh environments characterized by one or more of humid air, and immersion of the PSC film in a bio-based fluid.

IPC Classes  ?

• C08F 283/00 - Macromolecular compounds obtained by polymerising monomers on to polymers provided for in subclass
• H10K 10/46 - Field-effect transistors, e.g. organic thin-film transistors [OTFT]
• H10K 85/10 - Organic polymers or oligomers

Abstract

Provided herein are compositions for preventing or treating muscle conditions such as muscle damage, injury, or atrophy. In some embodiments, the compositions comprise a prostaglandin E2 (PGE2) compound and a myotoxin. In some embodiments, the muscle damage, injury, or atrophy is the result of a nerve injury, a surgical procedure, or a traumatic injury. Methods of promoting muscle regeneration and methods of increasing muscle mass are also provided herein.

IPC Classes  ?

• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
• A61K 31/245 - Amino benzoic acid types, e.g. procaine, novocaine
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/46 - 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
• A61K 31/47 - Quinolines; Isoquinolines
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients
• A61K 33/06 - Aluminium, calcium or magnesium; Compounds thereof
• A61K 33/24 - Heavy metals; Compounds thereof
• A61K 33/32 - Manganese; Compounds thereof
• A61K 35/583 - Snakes; Lizards, e.g. chameleons
• A61K 35/64 - Insects, e.g. bees, wasps or fleas
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 38/46 - Hydrolases (3)
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
• A61P 21/06 - Anabolic agents

Abstract

Devices, systems, and methods are provided for relieving peripheral nerve pain in a subject. In one example, the device includes a surface configured for placement against a subject's skin, an imaging element on the housing configured to transmit signals from the surface into the subject's body and receive reflected signals from the body, and one or more transducer elements configured to deliver focused ultrasound from the surface into the body. A controller is coupled to the imaging element to process the reflected signals to identify a target nerve within the body and coupled to the one or more transducer elements to control delivery of the focused ultrasound to the target nerve to relieve pain.

IPC Classes  ?

• A61N 7/02 - Localised ultrasound hyperthermia

Abstract

Organoid culture and image-processing methods and systems are described. Such methods and systems provide the ability for high-throughput characterization of a variety of phenotypes at single-organoid resolution.

IPC Classes  ?

• C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
• C12N 5/07 - Animal cells or tissues

Abstract

The present disclosure generally relates to engineered Cluster Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated (Cas) 12a proteins and system, and methods for use in gene editing and gene modulation for application to gene therapy. Related systems and methods of gene modulation are also disclosed.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/86 - Viral vectors

Abstract

Methods for preparing a variety of bryostatin compounds are provided. The subject methods provide for preparation of bryostatin 1 in multi-gram quantities in a low and unprecedented number of convergent synthetic steps from commercially available materials. The subject methods are scalable with low estimated material costs and can provide enough material to meet clinical needs. Also provided are a variety of bryostatin analog compounds, and prodrug forms thereof, which are synthetically accessible via the subject methods and pharmaceutical compositions including the same.

IPC Classes  ?

• C07D 407/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/365 - Lactones
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• A61P 31/18 - Antivirals for RNA viruses for HIV
• A61P 35/00 - Antineoplastic agents
• C07D 493/22 - Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings

Abstract

Methods of use, pharmaceutical formulations, and labeled versions of compounds are provided of compounds that penetrate the blood-brain barrier and influence the balance of excitatory versus inhibitory neurotransmission by enantiomer selective modulation of glutamate and GABA metabolism. In some embodiments, a glutamatergic false neurotransmitter is S-2-methylglutamate (S-2MeGlu). In some embodiments a GABAergic false neurotransmitters is R-4 aminopentanomic acid (4APA) or S-4 aminopentanomic acid (S-4APA), with high penetration of the blood brain barrier and low toxicity, therein providing useful pharmacologic or imaging agents.

IPC Classes  ?

• A61K 31/223 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-amino acids
• A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid (GABA), beta-alanine, epsilon-aminocaproic acid, pantothenic acid
• A61P 25/16 - Anti-Parkinson drugs
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Methods for identifying biosynthetic gene clusters that include genes for producing compounds that interact with specific target proteins are disclosed. Some methods relate to bioinformatics methods for identifying and/or prioritizing biosynthetic gene clusters. Related systems, components, and tools for the identification and expression of such gene clusters are also disclosed.

IPC Classes  ?

• G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
• C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
• G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
• G16B 10/00 - ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
• G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 30/10 - Sequence alignment; Homology search

Abstract

The present disclosure relates to glyconucleic acids, such as glycoRNA and glycoDNA described herein. Provided are glycosylated ribonucleic acid (glycoRNA)-related methods and compositions.

IPC Classes  ?

• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Abstract

The present invention relates to methods for identifying guide RNAs for use in site-directed RNA editing. In particular, the present invention relates to a high-throughput screening method for identifying guide RNAs effective for site directed A-to-I RNA editing, and methods of use for the identified guide RNAs.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof

Abstract

The present disclosure generally relates to compositions and methods simultaneous, multi-mode gene expression regulation (e.g., simultaneous upregulation and down regulation of multiple target genes). The present disclosure further relates to novel constructs for engineered multiplex CRISPR arrays.

IPC Classes  ?

• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 9/22 - Ribonucleases
• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C12N 15/90 - Stable introduction of foreign DNA into chromosome

Abstract

Methods are provided for the treatment of cancer and/or fibrosis. It is shown that there is increased CD63 expression both in lung cancer and pulmonary fibrosis, sarcoma, skin fibrosis, liver cancer and liver cirrhosis, NASH and NHFLD, and kidney fibrosis from hypertension and other etiologies. Inhibiting CD63 increases phagocytosis of lung cancer cells and lung fibroblasts; and can eliminates tumor cells and pathogenic fibrosis.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 9/22 - Ribonucleases

Abstract

Methods, systems, and devices, including computer programs encoded on a computer storage medium are provided for optimizing neurostimulation therapy for treatment of neurological and neurodegenerative diseases. Joint dynamic causal modeling and biophysics modeling are used for optimization of the stimulation targets and parameters. In particular, methods of performing neuromodulation to suppress b-band oscillations in the brain of a subject are provided.

Abstract

Methods, systems, and devices, including computer programs encoded on a computer storage medium are provided for optimizing neurostimulation therapy for treatment of neurological and neurodegenerative diseases. In particular, an algorithm is used to provide a predicted regional pathological density map of neuropathology and predict locations of future spreading. Neurostimulation therapy parameters including the location, strength, and frequency of neurostimulation can be adjusted accordingly to treat neuropathology and reduce aggregation and spreading.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G16H 30/00 - ICT specially adapted for the handling or processing of medical images

Abstract

Methods are provided for the classification, diagnosis, and/or prognosis of an individual who has PD or is suspected to have PD. The method comprises obtaining one or more biological samples from an individual who has or is suspected to have PD, quantifying the amount of one or more PD related polypeptides in the one or more biological samples, and integrating the results of the quantifying step with the age and sex of the individual from whom the biological sample was obtained from to generate a metric that indicates if that individual has PD wherein the integration is performed by a computer comprising software components for data analysis as a program of instructions executable by the computer.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61P 25/16 - Anti-Parkinson drugs
• C12N 9/88 - Lyases (4.)
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• G16B 25/10 - Gene or protein expression profiling; Expression-ratio estimation or normalisation
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid

Abstract

The present invention provides methods and related compositions for producing a sequencing ready DNA library in as few as three steps by combining adapter ligation, degradation, fill-in, and amplification of adapter-DNA fragments into a single reaction.

IPC Classes  ?

• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

inter aliainter alia, a copolymer, cell penetrating complexes, compositions and methods for the delivery of therapeutic, including small interfering RNA-based therapeutic agents, into a cell and related methods for treating cancer, including breast cancer and triple-negative breast cancer.

IPC Classes  ?

• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes

Abstract

Compositions, methods, and kits are provided for diagnosing vitreoretinal diseases and age-related pathologies. In particular, aqueous humor biomarkers have been identified that correlate with biological aging and age-related pathologies and morbidity. The use of such biomarkers may allow earlier intervention in treatment of aging-related diseases. In addition, methods of using aqueous humor biomarkers for prognosis, diagnosis, and monitoring treatment of vitreoretinal diseases are also provided.

Abstract

The present invention relates to the field of GPCR structure biology and signaling. In particular, the present invention relates to protein binding domains directed against or capable of specifically binding to a functional conformational state of a G-protein-coupled receptor (GPCR). More specifically, the present invention provides protein binding domains that are capable of increasing the stability of a functional conformational state of a GPCR, in particular, increasing the stability of a GPCR in its active conformational state. The protein binding domains of the present invention can be used as a tool for the structural and functional characterization of G-protein-coupled receptors bound to various natural and synthetic ligands, as well as for screening and drug discovery efforts targeting GPCRs. Moreover, the invention also encompasses the diagnostic, prognostic and therapeutic usefulness of these protein binding domains for GPCR-related diseases.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 14/72 - Receptors; Cell surface antigens; Cell surface determinants for hormones
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• G01N 23/20 - Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups , or by using reflection of the radiation by the materials
• G01N 33/566 - Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagent

Abstract

The invention generally relates to methods for assessing a neurological disorder by characterizing circulating nucleic acids in a blood sample. According to certain embodiments, methods tor assessing a neurological disorder include obtaining RNA present in a blood sample of a patient suspected of having a neurological disorder, determining a level of RNA present in the sample that is specific to brain tissue, comparing the sample level of RNA to a reference level of RNA specific to brain tissue, determining whether a difference exists between the sample level and the reference level, and indicating a neurological disorder if a difference is determined.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, nucleic acid molecules, such as cell-free nucleic acids, can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and/or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

IPC Classes  ?

• G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 25/00 - ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
• G16B 25/20 - Polymerase chain reaction [PCR]; Primer or probe design; Probe optimisation
• G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
• G16B 30/10 - Sequence alignment; Homology search
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or after the iboga alkaloid.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 33/06 - Aluminium, calcium or magnesium; Compounds thereof
• A61P 9/06 - Antiarrhythmics
• A61P 25/24 - Antidepressants

Abstract

Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slow or reverse brain aging by disorder by administering an iboga alkaloid and a cardioprotective agent, where analysis of brain image data is used to monitor and/or evaluate treatment effectiveness.

IPC Classes  ?

• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 33/06 - Aluminium, calcium or magnesium; Compounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 25/00 - Drugs for disorders of the nervous system

Abstract

Provided herein are methods for screening edited genomic sequences for their effect on expression of a target gene, and for designing a target sequence edit for introducing to a target sequence of a nucleic acid molecule. Also provided are compositions and cells including the edited sequences, and methods for their use in preventing or treating a disease.

IPC Classes  ?

• C12Q 1/686 - Polymerase chain reaction [PCR]
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A Purcell enhanced metamaterial scintillator structure comprises a conducting structure and a dielectric structure disposed adjacent to the conducting structure. The dielectric structure comprises a structure of scintillating nanoparticles.

IPC Classes  ?

• G01T 1/202 - Measuring radiation intensity with scintillation detectors the detector being a crystal
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals
• C09K 11/66 - Luminescent, e.g. electroluminescent, chemiluminescent, materials containing inorganic luminescent materials containing germanium, tin or lead

Abstract

The present disclosure provides methods of improving the structure and/or function of a joint tissue of a subject by administering to the subject an amount of a 15-PGDH inhibitor effective to inhibit 15-PGDH activity and/or reduce 15-PGDH levels in the subject. The methods described herein are useful for treating joint dysfunction and/or degeneration associated with aging, injury, disease, disorder, and/or condition.

IPC Classes  ?

• A61K 31/4365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

Inducible promoters for the coordinated expression of at least one heterologous gene in yeast and methods of using them are disclosed. In particular, the invention relates to sets of inducible promoters derived from S. cerevisiae and related species that can be induced in the presence of nonfermentable carbon sources.

IPC Classes  ?

• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression

Abstract

Embodiments herein describe systems and methods to generate a risk score for an individual to develop postoperative neurocognitive disorder (POND). Various embodiments obtain multi-omics data from an individual, such as genomics, transcriptomics, and proteomics. In certain embodiments, a machine learning algorithm is used to generate the risk score based on the multi-omics data. In further embodiments, clinical data is further used in the determination of the risk score.

IPC Classes  ?

• G06N 20/20 - Ensemble learning
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

The present disclosure provides methods of treating an individual for a muco-obstructive, the methods including: administering to the individual a b-adrenergic agonist or an adenylate cyclase activator, in combination with a cholinergic agonist to treat the individual for the muco-obstructive disorder.

IPC Classes  ?

• A61P 11/08 - Bronchodilators
• A61K 31/06 - Phenols the aromatic ring being substituted by nitro groups
• A61K 31/14 - Quaternary ammonium compounds, e.g. edrophonium, choline
• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

An independent control method of actuators in for example an everting robot or a soft everting robot is provided. The robot has distributed thereto or therewith multiple actuators which steer the robot. Energy is supplied from a single energy line to each of the multiple actuators. This energy enables force and displacement for each of the multiple actuators. Energy from the single energy line to each of the multiple actuators is controlled by a single control line. The single energy line and the single control line can be pneumatic sources or electric sources. The method allows for controlling greater than two actuators with at most two supply lines instead of one supply line per actuator. Reduction of the number of supply lines and complexity of subsystems provides numerous advantages in terms of cost, size, stiffness, friction, amount of material used, ease for tip mounts as well as mobility.

IPC Classes  ?

• B25J 18/02 - Arms extensible
• B25J 18/06 - Arms flexible
• B25J 9/06 - Programme-controlled manipulators characterised by multi-articulated arms
• B25J 9/14 - Programme-controlled manipulators characterised by positioning means for manipulator elements fluid
• D06G 3/04 - Turning inside-out flexible tubular or other hollow articles pneumatically
• F01B 19/04 - Positive-displacement machines or engines of flexible-wall type with tubular flexible members

Abstract

Methods of treating a subject for a cellular proliferative disease, e.g., a cancer, are provided. Aspects of the methods include: administering to the subject an agent that modulates DSIF complex activity, e.g., activity of a DSIF complex made up of a SPT4 and SPT5 protein, such as a DSIF complex made up of Supt4h and Supt5h, in a manner sufficient to treat the subject for the cellular proliferative disease. Also provided are compositions for practicing the methods.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61P 35/00 - Antineoplastic agents
• C12N 15/63 - Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum

Abstract

Provided herein are, inter alia, methods for treating subjects in need of an IL-1 inhibitor therapy or an IL-6 inhibitor therapy, and related methods. The methods include determining whether the subject is at risk for drug-related hypersensitivity by assaying for the presence of certain HLA alleles.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present disclosure relates to methods of inhibiting reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in a subject. In one embodiment, the method involves administering an inhibitor of Elongation of Very Long Chain Fatty Acids Protein 1 (ELOVL1) to a subject having or at risk of having a condition mediated by reactive astrocytes, where the ELOVL1 inhibitor is administered in an amount effective to inhibit reactive astrocyte mediated neuronal and/or oligodendrocyte cell death in the subject. In another embodiment, the method involves administering an inhibitor of lipoapoptosis to a subject having or at risk of having a condition mediated by reactive astrocytes, where the inhibitor of lipoapoptosis is administered in an amount effective to inhibit reactive astrocyte mediate neuronal and/or oligodendrocyte cell death in the subject.

IPC Classes  ?

• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/201 - Carboxylic acids, e.g. valproic acid having a carboxyl group bound to an acyclic chain of seven or more carbon atoms, e.g. stearic, palmitic or arachidic acid having one or two double bonds, e.g. oleic or linoleic acid
• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Compositions and methods are provided for the reversible modification of RNA to enhance RNA in-solution and enzymatic stability by reaction with acylimidazoles, sulfonyltriazoles, or sulfonylimidazoles. 2′-OH acylation protects RNA from hydrolytic and enzymatic degradation. Water-soluble organocatalysts can accelerate the reversal of acylation adducts and functionally restore RNAs, alternatively the acylation is spontaneously reversed in a cellular environment. Chemically tuned 2′-OH acylation can be spontaneously released in cells to restore RNA biological functions including translation. mRNA can be selectively modified at the 2′-OH of poly(A)-tail for enhanced in-cell stability and enhanced total protein output.

IPC Classes  ?

• C12N 15/11 - DNA or RNA fragments; Modified forms thereof
• C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical

Abstract

Engineered proteins, polynucleotides encoding such proteins, and methods of use thereof are provided, which engineered proteins enhance the sensitivity of a cell to IL-2.

IPC Classes  ?

• C07K 14/55 - IL-2
• C07K 14/715 - Receptors; Cell surface antigens; Cell surface determinants for interferons

Abstract

Blockchain-based, smart contract platforms have great promise to remove trust and add transparency to distributed applications. However, this benefit often comes at the cost of greatly reduced privacy. Techniques for implementing a privacy-preserving smart contract is described. The system can keep accounts private while not losing functionality and with only a limited performance overhead. This is achieved by building a confidential and anonymous token on top of a cryptocurrency. Multiple complex applications can also be built using the smart contract system.

IPC Classes  ?

• G06Q 20/38 - Payment architectures, schemes or protocols - Details thereof
• G06Q 20/06 - Private payment circuits, e.g. involving electronic currency used only among participants of a common payment scheme
• G06Q 20/36 - Payment architectures, schemes or protocols characterised by the use of specific devices using electronic wallets or electronic money safes
• H04L 9/00 - Arrangements for secret or secure communications; Network security protocols
• H04L 9/06 - Arrangements for secret or secure communications; Network security protocols the encryption apparatus using shift registers or memories for blockwise coding, e.g. D.E.S. systems
• H04L 9/32 - Arrangements for secret or secure communications; Network security protocols including means for verifying the identity or authority of a user of the system

Abstract

Provided herein are retroviral vector systems useful for producing universal pseudotyped retroviruses for cell and gene therapies. The vector systems include an envelope plasmid and a packaging plasmid, where at least one of these plasmids encodes a binding moiety that directly binds a target cell through a cell binding domain, or that indirectly binds a target cell through an antibody binding domain. Also provided are related retrovirus-packaging cells, retroviruses, virus-like particles, and methods for their production and use in preventing or treating a disease.

IPC Classes  ?

• C12N 15/867 - Retroviral vectors
• A61K 31/711 - Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links

Abstract

Provided herein are compositions and methods for modifying T cells.

IPC Classes  ?

• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A method for assessing fatigue of a subject is provided. The method includes providing a device comprising a first electrode, a second electrode, and a circuit operably coupled to the first and second electrodes, the first and second electrodes configured to detect an electrical activity associated with an eye blink of a subject, and the circuit is configured to process a signal from the first electrode and the second electrode; determining a blink event based on the electrical activity; and assessing a degree of fatigue of the subject, based on the blink event. A headset including circuitry, such as a processor and a memory storing instructions to cause the headset to perform the above method are also provided. Also provided are systems and kits that include the devices. The methods, devices, headsets, systems and kits find use in a variety of different applications.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/16 - Devices for psychotechnics; Testing reaction times
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/18 - Devices for psychotechnics; Testing reaction times for vehicle drivers

Abstract

The present disclosure provides methods and compositions for treating SCID-X1 in subjects, comprising genetically modifying cells from the subjects ex vivo by integrating a full-length, codon-optimized IL2RG cDNA at the endogenous IL2RG locus.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• A61K 35/28 - Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C12N 5/0789 - Stem cells; Multipotent progenitor cells
• C12N 9/22 - Ribonucleases
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

In certain examples, methods and apparatuses, such as circuits, are directed to scanning in a field of view (FoV) by using a pattern that improves sensing in a region of interest (RoI) within the FoV. In one example, a signal having multiple frequency components and a scan-pattern design are used, with a balanced or optimized set of attributes including a sampling density attribute, to scan a RoI in a FoV by sampling or traversing the RoI more times than other regions in the FoV. In more specific examples, circuitry finds the scan-pattern design based on an algorithm that processes different parameters involving at least one of amplitude and phase and processes a. number of different frequency components related to or including the multiple frequency components, wherein the number of different frequency components is from three to a threshold limit whereat processing different frequency components provides negligible improvement.

IPC Classes  ?

• G01S 17/89 - Lidar systems, specially adapted for specific applications for mapping or imaging
• B81B 7/02 - Microstructural systems containing distinct electrical or optical devices of particular relevance for their function, e.g. microelectro-mechanical systems (MEMS)
• G01S 7/481 - Constructional features, e.g. arrangements of optical elements

Abstract

Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

IPC Classes  ?

• G01N 33/574 - Immunoassay; Biospecific binding assay; Materials therefor for cancer
• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

Compositions comprising an iboga alkaloid and a cardioprotective agent are provided. Use of the compositions in treating neuropsychiatric disorders are described, where the cardioprotective agent is administered before, during and/or after the iboga alkaloid.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/135 - Amines, e.g. amantadine having aromatic rings, e.g. methadone
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61K 31/33 - Heterocyclic compounds

Abstract

Methods for treating a neuropsychiatric disorder by administering an iboga alkaloid and a cardioprotective agent in conjunction with analysis of brain image data is described. Also described are methods to improve brain health and to slow or reverse brain aging by disorder by administering an iboga alkaloid and a cardioprotective agent, where analysis of brain image data is used to monitor and/or evaluate treatment effectiveness.

IPC Classes  ?

• A61P 25/00 - Drugs for disorders of the nervous system
• A61K 31/55 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
• A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 9/06 - Antiarrhythmics
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Provided are nucleic acids encoding kinase-modulated bioluminescent indicator (KiMBI) polypeptides. In certain embodiments, a nuclei acid of the present disclosure encodes a KiMBI polypeptide comprising a first bioluminescent enzyme fragment, a phospho-binding domain, a 5 second bioluminescent enzyme fragment capable of forming an active bioluminescent enzyme with the first fragment via enzyme fragment complementation, and a kinase substrate bound by the phospho-binding domain when phosphorylated. KiMBI polypeptide may be fused to one or more fluorescent proteins, e.g., which exhibit resonance energy transfer (RET). Also provided are KiMBI polypeptides encoded by the nucleic acids of the present disclosure. Cells that express 10 a KiMBI polypeptide are also provided, as are non-human animals comprising such cells. Also provided are methods of assessing activity of a kinase of interest in a non-huma animal, and methods of assessing a test agent for the ability to inhibit a kinase of interest in a non-human animal.

IPC Classes  ?

• G01N 21/76 - Chemiluminescence; Bioluminescence
• C12Q 1/66 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving luciferase
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

Provided are fusion proteins including an amino acid sequence of an ectodomain of Spike protein of a coronavirus, such as SARS-CoV-2, joined to an amino acid sequence of a ferritin subunit polypeptide. Nanoparticles including such fusion proteins, with surface-exposed trimers of the ectodomain of the Spike protein of the coronavirus, are also provided. Also provided are nucleic acids and vectors encoding the fusion proteins, cells containing such nucleic acid and vectors, immunogenic compositions including the fusion proteins, the nanoparticles, or the vectors, as well as corresponding methods and kits.

IPC Classes  ?

• C07K 14/165 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus

Abstract

Systems and methods are provided for altering the shape of a target tissue structure of a subject, e.g., a nasal septum or other nasal tissue that include securing a first end of a shaping element to tissue adjacent the structure; manipulating the tissue to alter a shape of the structure; and applying a force to the shaping element to maintain the altered shape of the structure.

IPC Classes  ?

• A61F 2/18 - Internal ear or nose parts, e.g. ear-drums
• A61F 2/28 - Bones

Abstract

Systems and methods for neuronavigation in accordance with embodiments of the invention are illustrated. Targeting systems and methods as described herein can generate personalized stimulation targets for the treatment of mental conditions. In many embodiments, direct stimulation of a personalized the stimulation target indirectly impacts a brain structure that is more difficult to reach via the stimulation modality. In various embodiments, the mental condition is major depressive disorder. In a number of embodiments, the mental condition is suicidal ideation.

IPC Classes  ?

• A61B 34/20 - Surgical navigation systems; Devices for tracking or guiding surgical instruments, e.g. for frameless stereotaxis
• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• A61N 1/20 - Applying electric currents by contact electrodes continuous direct currents
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 2/00 - Magnetotherapy
• G01R 33/48 - NMR imaging systems
• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques

Abstract

Provided are recombinant polypeptides that comprise a protein of interest, a protein localization tag, and a protease cleavage site disposed between the protein of interest and the protein localization tag. In certain embodiments, the recombinant polypeptides further comprise a protease, where the protease cleavage site is a cleavage site for the protease. Also provided are nucleic acids that encode the recombinant polypeptides, cells that comprise such nucleic acids, and compositions (e.g., pharmaceutical compositions) that comprise such cells. Methods of regulating cellular localization of a protein of interest, and methods of administering a regulatable cell-based therapy to an individual in need thereof, are also provided.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 14/725 - T-cell receptors
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

A method is provided. The method includes determining an open circuit voltage of a battery of a vehicle. The method also includes determining a voltage of a current provided to the battery of the vehicle. The method further includes determining a impedance indicator based on the voltage, the open circuit voltage, and the current provided to the battery of the vehicle. The method further includes determining a health of the battery based on the impedance indicator.

IPC Classes  ?

• G01R 31/392 - Determining battery ageing or deterioration, e.g. state of health
• G01R 31/3842 - Arrangements for monitoring battery or accumulator variables, e.g. SoC combining voltage and current measurements
• G01R 31/389 - Measuring internal impedance, internal conductance or related variables

Abstract

A vertically selective liftoff scribing process is provided. One application is the fabrication of solar cells and solar modules. The basis of this technology is absorption of an indirectly focused laser beam in the front electrode material of the device, which enables removal of this layer (e.g., a P1 scribe) or removal of layers above the front electrode while leaving the front electrode intact (e.g., a P2 or P3 scribe). The laser fluence can be selected to choose between these alternatives, and further fine tuning is possible depending on details of the device structure.

IPC Classes  ?

• H01L 31/0463 - PV modules composed of a plurality of thin film solar cells deposited on the same substrate characterised by special patterning methods to connect the PV cells in a module, e.g. laser cutting of the conductive or active layers
• B23K 26/0622 - Shaping the laser beam, e.g. by masks or multi-focusing by direct control of the laser beam by shaping pulses
• B23K 26/40 - Removing material taking account of the properties of the material involved
• H01L 31/0224 - Electrodes
• H01L 31/05 - Electrical interconnection means between PV cells inside the PV module, e.g. series connection of PV cells

Abstract

The present disclosure provides methods for treating a disease or disorder or enhancing phagocytosis of a target cell. The methods comprise administering or contacting an immune cell with an inhibitor of paired immunoglobulin-like type 2 receptor-alpha (PILRA).

IPC Classes  ?

• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

The present embodiments relate generally to stable cycling of metallic lithium under high current densities and realistic cell conditions based on a flower-like nanostructured hard carbon host (CF). In embodiments, CF is both intercalated with lithium ions and plated with lithium metal to render a hybrid lithium-ion/lithium-metal anode capacity. The hybrid cells showed >99% CE up to 12 mA/cm2(4 mAh/cm2) and >99.5% CE up to 16 mA/cm2(2.5 mAh/cm2) with commercial carbonate electrolyte. The stability of the hybrid anodes was attributed to uniform lithium plating morphology and fast ion diffusion pathways enabled by the open-pore nanostructures of CF. Moreover, the CF||NMC811 hybrid cells (2 mAh/cm2) showed excellent performance (~70% capacity retention after 200 cycles, 100% SOC, room temperature) at 10 mA/cm2 current densities (<20 min charging for 100% SOC), while demonstrating ~4 times anode specific capacity and much better cyclic stability compared to graphite] |NMC lithium-ion cells at such current.

IPC Classes  ?

• H01M 10/052 - Li-accumulators
• H01M 10/058 - Construction or manufacture
• H01M 4/13 - Electrodes for accumulators with non-aqueous electrolyte, e.g. for lithium-accumulators; Processes of manufacture thereof
• H01M 4/139 - Processes of manufacture
• H01M 4/36 - Selection of substances as active materials, active masses, active liquids
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 4/02 - Electrodes composed of, or comprising, active material

Abstract

Laser feedback stabilization combined with isolation is provided in an integrated approach. The main element is a high quality factor resonator that acts as a circulator under high optical power due to the Kerr nonlinearity. This resonator can then be coupled to a laser or optical gain media to provide isolation and combined with a feedback path to stabilize the lasing mode.

IPC Classes  ?

• H01S 3/13 - Stabilisation of laser output parameters, e.g. frequency or amplitude
• H01S 3/08 - Construction or shape of optical resonators or components thereof
• G02F 1/35 - Non-linear optics
• H03G 3/12 - Manually-operated control in untuned amplifiers having semiconductor devices incorporating negative feedback

Abstract

Methods are provided herein for modulating the epigenome of immune cells by administration of an immunostimulatory composition comprising adjuvants, e.g. vaccine adjuvants, to stimulate broad and persistent innate immunity against pathogens unrelated to antigens present in the composition.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 39/12 - Viral antigens
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof

Abstract

Methods and compositions are provided for the treatment of glaucoma and other optic neuropathies.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

Abstract

Humanized or chimeric anti-CD47 monoclonal antibodies are provided. The antibodies bind to and neutralize human CD47, and find use in various therapeutic methods. Preferred are non-activating antibodies. Embodiments of the invention include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the humanized or chimeric anti-CD47 monoclonal antibodies; and cell lines that produce these monoclonal antibodies. Also provided are amino acid sequences of the antibodies.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C07K 16/46 - Hybrid immunoglobulins
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Abstract

The present disclosure provides systems, compositions and methods for regulating expression of a target polynucleotide in a cell. The systems, compositions and methods comprise a chimeric receptor polypeptide comprising a G-protein coupled receptor (GPCR) or a fragment thereof, a chimeric adaptor polypeptide, at least one actuator moiety and a cleavage moiety.

IPC Classes  ?

• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C12N 9/22 - Ribonucleases

Abstract

Systems and methods for generating knowledge graphs and text summaries from document databases are provided. In one embodiment, a system for generating knowledge graphs and text summaries includes: a device, including: a processor; and a memory containing a knowledge graph and text summary generating application, where the knowledge graph and text summary generating application directs the processor to: query a global network of biomedical relationships; construct a knowledge graph and a citation graph; apply processes to learn local context-based weights and compute summarizations; and provide results via a display.

IPC Classes  ?

• G06F 16/34 - Browsing; Visualisation therefor
• G06F 16/36 - Creation of semantic tools, e.g. ontology or thesauri

Abstract

De novo designed polypeptides that bind to IL-2 receptor βγc heterodimer (IL-2Rβγc), IL-4 receptor αγc heterodimer (IL-4Rαγc), or IL-13 receptor α subunit (IL-13Rα) are disclosed, as are methods for using and designing the polypeptides.

IPC Classes  ?

• C07K 14/55 - IL-2
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 47/62 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
• C07K 14/54 - Interleukins (IL)

Abstract

The present invention relates to a method for selectively transducing retinal and optic nerve head (ONH) astrocytes using adeno-associated virus serotype 5 (AAV5) in combination with a modified glial fibrillary acidic protein promoter (gfaABC1D) for delivery of gene therapies (recombinant DNA, shRNA, Crispr/Cas9) to treat glaucoma or other optic neuropathies

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/02 - Ophthalmic agents
• C12N 9/22 - Ribonucleases
• C12N 15/86 - Viral vectors

Abstract

Methods for labeling and imaging the accessible genome using a transposase are disclosed. In some embodiments, a bifunctional transposase complex or transposome is used to insert adaptors comprising chemical tags selectively at accessible sites in the genome where active regulatory DNA is located. Various chemical tags can be used for labeling DNA at insertion sites, including, for example, fluorescent dyes for fluorescence imaging, metal particles for electron microscopy or magnetic manipulation of DNA, isotopic labels, or biotin or other ligands, haptens, substrates, or inhibitors that are recognized by streptavidin, antibodies, enzymes, or receptors. Labeling DNA in this manner can be used to provide spatial information regarding the positioning of regulatory DNA in the genome and makes possible the imaging and sorting of cells based on the status of their regulatory DNA.

IPC Classes  ?

• C12N 9/22 - Ribonucleases
• C07K 1/13 - Labelling of peptides
• C12N 15/90 - Stable introduction of foreign DNA into chromosome
• C12Q 1/6806 - Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay

Abstract

Compounds useful as contrast agents in image-guided surgery are provided. The compounds comprise a latent cationic lysosomotropic fragment that is detectable upon cleavage by lysosomal proteases within treated tissues, particularly within tumors and other diseased tissues. Also provided are compositions comprising the compounds and methods for using the compounds, for example in dynamically monitoring protease activity in vivo during image-guided tumor resection surgery.

IPC Classes  ?

• G01N 33/532 - Production of labelled immunochemicals
• C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
• C07K 5/065 - Dipeptides the side chain of the first amino acid containing carbocyclic rings, e.g. Phe, Tyr
• C09B 23/01 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain
• C09B 23/08 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups more than three CH groups, e.g. polycarbocyanines
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Abstract

A salt-philic solvent-phobic (SP2) polymer coating on a lithium anode, sodium anode, or a silicon anode selectively transports salt over solvent and is configured to promote salt-derived SEI formation on the anode. The SP2 coating can include a polymer backbone, a first side chain comprising a first moiety having salt affinity, and a second side chain comprising a second moiety immiscible with polar aprotic solvents.

IPC Classes  ?

• C09D 7/20 - Diluents or solvents
• C09D 201/00 - Coating compositions based on unspecified macromolecular compounds
• C08G 77/04 - Polysiloxanes
• C08F 220/06 - Acrylic acid; Methacrylic acid; Metal salts or ammonium salts thereof
• H01M 4/62 - Selection of inactive substances as ingredients for active masses, e.g. binders, fillers
• H01M 4/134 - Electrodes based on metals, Si or alloys
• H01M 10/052 - Li-accumulators
• H01M 4/02 - Electrodes composed of, or comprising, active material

Abstract

in vivo ex vivo ex vivo delivery of a molecular cargo into endo-lysosomal compartments of LRP1-expressing cells. A molecular cargo of interest is linked to a substrate or inhibitor for recognition and transport via human transglutaminase 2 (TG2).

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• A61K 38/43 - Enzymes; Proenzymes; Derivatives thereof
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin

Abstract

Compositions and methods are provided for modulating growth of a genetically modified bacterial cell present in a human organ, for modulating growth of a genetically modified bacterial cell in an organ (e.g., gut), for displacing at least a portion of a population of bacterial cells in an organ, and for facilitating gut colonization by a genetically modified bacterial cell. Also provided are genetically modified bacterial cells, e.g., cells that include a heterologous carbohydrate-utilization gene or gene set that provides for the ability to utilize as a carbon source a rare carbohydrate of interest that is utilized as a carbon source by less than 50% of bacterial cells present in a human microbiome.

IPC Classes  ?

• C12N 9/24 - Hydrolases (3.) acting on glycosyl compounds (3.2)
• A61K 35/741 - Probiotics
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system
• C12N 1/20 - Bacteria; Culture media therefor
• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Abstract

Methods of differentiating pluripotent stem cells into thymic epithelial progenitor cells are provided.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system

Abstract

An antigen-specific T cell binding agent is provided, where a multivalent ‘spheromer’ system utilizes a scaffold of a self-assembling polypeptide nanoparticle, for example using selfassembling ferritin polypeptides. The system is compatible with current pMHC reagents, including both MHC-I and MHC-II molecules, and streptavidin reagents that allow ease-of-use. The spheromer assembly pipeline provides a consistent reagent across multiple batches of synthesis with ease of production. The defined geometry of the scaffold allows precise site-directed conjugation of pMHC, leading to a homogenous reagent. The spheromer binds cognate TCRs with a significantly higher avidity than a tetrameric reagent.

IPC Classes  ?

• C07K 14/79 - Transferrins, e.g. lactoferrins, ovotransferrins
• C07K 14/74 - Major histocompatibility complex (MHC)
• C12N 9/10 - Transferases (2.)
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Miscible antifoams are provided that do not separate out of a target liquid and that are easy to incorporate in the target liquid. A method or system involves mixing a liquid (‘a miscible antifoam’) into a target foaming liquid. This miscible antifoam is engineered/chosen such that it has both a higher surface tension and is more volatile than the target liquid, or engineered such that it has both a lower surface tension and is less volatility than the target liquid. The miscible antifoam leads to surface tension gradients that cause bubble rupture up to 10 times faster than the target liquid without the antifoam. Further, the miscible antifoams are easy to incorporate and do not separate out from the target liquid during operation—both of which are key limitations faced by existing antifoams.

IPC Classes  ?

• C10M 169/00 - Lubricating compositions characterised by containing as components a mixture of at least two types of ingredient selected from base-materials, thickeners or additives, covered by the preceding groups, each of these compounds being essential
• B01D 19/04 - Foam dispersion or prevention by addition of chemical substances
• C10L 1/08 - Liquid carbonaceous fuels essentially based on blends of hydrocarbons for compression ignition
• C10M 127/06 - Alkylated aromatic hydrocarbons

Abstract

The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.

IPC Classes  ?

• A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• C07K 14/52 - Cytokines; Lymphokines; Interferons

Abstract

Injection of silicon oil (SO) to the anterior chamber of an eye efficiently induces intraocular pressure (TOP) elevation. This effect occurs without causing overt ocular structural damage or inflammatory responses while simulating acute glaucomatous changes that human patients develop over years by inducing progressive RGC and ON degeneration and visual functional deficits within weeks. The anterior segments of the experimental eyes are not substantially affected, leaving clear ocular elements that allow easy and reliable assessment of in vivo visual function and morphology. More importantly, this is the only reversible ocular hypertension model by removing SO from the anterior chamber and particularly useful for testing neuroprotection treatment together with lowering TOP treatment. In summary, the acute ocular hypertension glaucoma model replicates secondary post-operative glaucoma. It is straightforward and reversible, does not require special equipment or repeat injections, and may be applicable to a range of animal species with only minor modifications.

IPC Classes  ?

• A61F 9/007 - Methods or devices for eye surgery
• G09B 23/30 - Anatomical models

Abstract

Compositions and methods are provided for preventing or treating obesity and/or overweight, and managing body weight. Compositions comprise partial agonists of the leptin receptor (lepr), including variant leptin polypeptides, which partial agonists elicit sub-maximal signaling at saturating ligand concentrations, and bias the response to STAT3 signaling. Human leptin protein variants, for example leptin modified to increase affinity at site 2 binding site(s) and decrease binding at site 3 binding site(s), preferentially suppress phosphorylation of SHP2, ERK, and STAT1 relative to STAT3, resulting in a biased signal that selectively activates pathways associated with satiety, with decreased activation of pathways associated with leptin resistance. The variant proteins find use in the suppression of appetite, and can provide for therapeutic weight loss.

IPC Classes  ?

• A61K 38/22 - Hormones
• C07K 14/57 - IFN-gamma
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Methods and systems are presented for using optical parametric amplifiers in various ways that enhance a native quadratic coupling strength so that a photonic component of interest can be measured or otherwise observed without demolishing the component of interest at a system output. For example such components may include a number of signal Bogoliubov excitations, a pump modular quadrature, or a signal quadrature squared.

IPC Classes  ?

• G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
• G02F 1/35 - Non-linear optics
• G06N 10/20 - Models of quantum computing, e.g. quantum circuits or universal quantum computers
• B82Y 10/00 - Nanotechnology for information processing, storage or transmission, e.g. quantum computing or single electron logic
• G06N 10/60 - Quantum algorithms, e.g. based on quantum optimisation, or quantum Fourier or Hadamard transforms
• G06N 10/80 - Quantum programming, e.g. interfaces, languages or software-development kits for creating or handling programs capable of running on quantum computers; Platforms for simulating or accessing quantum computers, e.g. cloud-based quantum computing

Abstract

Provided are methods of assessing an enzyme for plastic-degrading activity. In certain embodiments, the methods comprise contacting a plastic with the enzyme under conditions suitable for plastic-degrading enzyme activity, and assessing for degradation of the plastic by the enzyme. Also provided are plastic-degrading enzymes and methods of using the same. As a non-limiting example, the plastic-degrading enzymes are polyester-degrading enzymes. As an example, polylactic acid (PLA)-degrading enzymes and methods of using the same. As another example, polyethylene terephthalate (PET)-degrading enzymes and methods of using the same.

IPC Classes  ?

• C12N 15/52 - Genes encoding for enzymes or proenzymes
• C08J 11/10 - Recovery or working-up of waste materials of polymers by chemically breaking down the molecular chains of polymers or breaking of crosslinks, e.g. devulcanisation
• C12N 9/18 - Carboxylic ester hydrolases

Abstract

Compositions and methods are provided for the identification of peptide sequences that are presented to T cells in an MHC context.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• H01J 49/00 - Particle spectrometers or separator tubes
• H01J 49/16 - Ion sources; Ion guns using surface ionisation, e.g. field-, thermionic- or photo-emission

Abstract

Devices and methods for treating obstructive sleep apnea, habitual mouth breathing, and/or myofunctional therapy includes a body including an anterior end, a posterior end, and lateral portions shaped for introduction into a subject's oral cavity to position the anterior end adjacent front teeth of the subject and the posterior end adjacent the pharyngeal airway of the subject with or without the posterior end adjacent the pharyngeal airway. Sensors and/or stimulators may be provided, to generate electrical current, chemical release, vibration, and/or other stimulations, e.g., to activate neuromuscular contraction, stimulate salivation and subsequent swallowing movement, and/or induce partial wakefulness of the subject and/or to record data regarding the subject's tongue movements and/or position. Optionally, an extraoral sensor device may be provided for placement around the face, nose, check, abdomen, or neck, which may be paired with the intraoral device to detect the respiratory effort related airway obstruction.

IPC Classes  ?

• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers

Abstract

Methods are provided for the cell-based delivery of collagen VII for the treatment of Epidermolysis Bullosa and corneal erosion. The disclosure also provides a composition and a pharmaceutical composition comprises, comprise, or alternatively consist essentially of, or yet further consist of a keratinocyte sheet or a corneal cell sheet.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Improved resolution of a time-varying optical measurement is provided with optical intensity modulator(s) having a bandwidth greater than that of the detector array(s). The modulator configuration can have high photon collection efficiency, e.g. by using polarization modulation to split the incident light into several time-gated channels.

IPC Classes  ?

• G01J 3/44 - Raman spectrometry; Scattering spectrometry
• G01J 3/28 - Investigating the spectrum
• G01N 21/64 - Fluorescence; Phosphorescence

Abstract

Compositions, methods, and kits are provided for treating infections and cancer with metallic nanoclusters. In particular, metallic nanoclusters having a size of less than 10 nm that are conjugated to adenosine triphosphate (ATP) or an analogue thereof can be used to eradicate a cell in a growth arrest phase such as infectious bacterial or fungal cells. Such nanoclusters can also induce endoplasmic reticulum stress and inhibit growth of cancerous cells. Additionally, such metallic nanoclusters can be used to inhibit a purinergic P2X7 receptor and FtsH protease.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

Compositions and methods for treating a cardiomyopathy, such as dilated cardiomyopathy (DCM) are provided. Embodiments of the present disclosure provide compositions having a bisphosphonate compound, wherein the compound acts as a structure-based corrector therapeutic by targeting a genetic mutation associated with familial DCM.

IPC Classes  ?

• A61K 31/66 - Phosphorus compounds
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 9/14 - Particulate form, e.g. powders
• A61B 5/02 - Measuring pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography; Heart catheters for measuring blood pressure

Abstract

Provided are nucleic acids encoding chimeric cytokine receptors (CCRs) capable of signaling in the absence of their cognate cytokines. In some embodiments, provided are one or more nucleic acids encoding a first subunit of a chimeric cytokine receptor and a second subunit of the chimeric cytokine receptor. The first subunit comprises a first heterologous dimerization domain and a first cytokine receptor intracellular signaling domain (ICD). The second subunit comprises a second heterologous dimerization domain cognate for the first heterologous dimerization domain, and a second cytokine receptor ICD. The CCRs find use in a variety of contexts, including but not limited to, increasing the persistence of therapeutic cells. Accordingly, also provided are methods of administering a cell-based therapy, the methods comprising administering therapeutic cells (e.g., CAR-T cells, etc.) expressing the CCRs to a subject in need thereof.

IPC Classes  ?

• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy